Laverock Therapeutics, a UK-based gene control company, has expanded its seed funding round, raising over £20 million (US$27.5 million).

The round was led by Calculus Capital, with support from existing investors Eli Lilly and Company, Mercia Ventures, Eos Advisory, Maven Capital Partners, and new investor Norcliffe Capital.

The company reported advancements in its T-cell and macrophage programs, showing improved tumor control in both hematological and solid cancer models.

Its platform uses programmable and tunable gene silencing technologies to improve the precision and safety of advanced therapies.

The funding will support further platform development and partnership opportunities.

🔗 Source: Laverock Theurapetics